€84.00
Your prediction
Financial data and news for Protagonist
sharewise wants to provide you with the best news and tools for Protagonist, so we directly link to the best financial data sources.
Financials
News
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Recent market speculation linking Johnson & Johnson (NYSE: JNJ) to a complete acquisition of its partner, Protagonist Therapeutics (NASDAQ: PTGX), offers a valuable glimpse into a core corporate
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Arturo Molina, Chief Medical Officer of Protagonist Therapeutics (NASDAQ:PTGX), directly sold 9,514 shares in an open-market transaction on Jan. 20, 2026, for an approximate value of $784,700
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
Clinical-stage biotech Protagonist Therapeutics (NASDAQ: PTGX) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense